Cartesian Therapeutics (RNAC) EBITDA (2015 - 2026)
Cartesian Therapeutics (RNAC) reported EBITDA of -$39.2 million for Q1 2026, down 121.68% year-over-year from $180.7 million in Q1 2025, and up 57.66% on a QoQ basis from -$92.6 million in Q4 2025.
Cartesian Therapeutics (RNAC) has 12 years of EBITDA data on file, last reported at -$39.2 million in Q1 2026.
- Quarterly EBITDA fell 121.68% year-over-year to -$39.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$151.8 million (down 296.32% YoY) and the FY2025 annual result came in at -$130.3 million, down 68.19% from the prior year.
- EBITDA climbed to -$39.2 million in Q1 2026 per RNAC's latest filing, from -$92.6 million in the prior quarter.
- Across five years, EBITDA topped out at $28.7 million in Q1 2022 and bottomed at -$177.6 million in Q4 2023.
- The 5-year median for EBITDA is -$11.4 million (2023), against an average of -$25.4 million.
- The widest annual swing landed in 2023, when EBITDA tumbled 3128.85%; it then soared 221.34% in 2024.
- Tracing RNAC's EBITDA over 5 years: stood at $5.9 million in 2022, then plunged by 3128.85% to -$177.6 million in 2023, then surged by 94.22% to -$10.3 million in 2024, then plunged by 801.49% to -$92.6 million in 2025, then jumped by 57.66% to -$39.2 million in 2026.
- Per Business Quant, the three latest RNAC EBITDA figures stand at -$39.2 million (Q1 2026), -$92.6 million (Q4 2025), and -$35.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Cartesian Therapeutics | 202.49 Mn | 202.49 Mn | - | -39.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.19 Mn |
| Dec 31, 2025 | -92.57 Mn |
| Sep 30, 2025 | -35.91 Mn |
| Jun 30, 2025 | 15.90 Mn |
| Mar 31, 2025 | -17.68 Mn |
| Dec 31, 2024 | -10.27 Mn |
| Sep 30, 2024 | -24.20 Mn |
| Jun 30, 2024 | 13.85 Mn |
| Mar 31, 2024 | -56.83 Mn |
| Dec 31, 2023 | -177.64 Mn |
| Sep 30, 2023 | -9.02 Mn |
| Jun 30, 2023 | -11.41 Mn |
| Mar 31, 2023 | -21.67 Mn |
| Dec 31, 2022 | 5.87 Mn |
| Sep 30, 2022 | -7.94 Mn |
| Jun 30, 2022 | 8.72 Mn |
| Mar 31, 2022 | 28.75 Mn |
| Dec 31, 2021 | 12.23 Mn |
| Sep 30, 2021 | -17.90 Mn |
| Jun 30, 2021 | 4.58 Mn |
| Mar 31, 2021 | -24.60 Mn |
| Dec 31, 2020 | -15.43 Mn |
| Sep 30, 2020 | -9.76 Mn |
| Jun 30, 2020 | -24.05 Mn |
| Mar 31, 2020 | -19.68 Mn |
| Dec 31, 2019 | -14.88 Mn |
| Sep 30, 2019 | -12.00 Mn |
| Jun 30, 2019 | -16.39 Mn |
| Mar 31, 2019 | -12.05 Mn |
| Dec 31, 2018 | -14.69 Mn |
| Sep 30, 2018 | -16.04 Mn |
| Jun 30, 2018 | -18.87 Mn |
| Mar 31, 2018 | -15.87 Mn |
| Dec 31, 2017 | -19.56 Mn |
| Sep 30, 2017 | -14.67 Mn |
| Jun 30, 2017 | -16.00 Mn |
| Mar 31, 2017 | -15.00 Mn |
| Dec 31, 2016 | -14.05 Mn |
| Sep 30, 2016 | -7.70 Mn |
| Jun 30, 2016 | -6.75 Mn |
| Mar 31, 2016 | -7.25 Mn |
| Dec 31, 2015 | -7.20 Mn |
| Sep 30, 2015 | -6.53 Mn |
| Jun 30, 2015 | -6.32 Mn |